iRhythm Technologies, Inc. (IRTC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 121.78 |
| Open | 122.27 |
| Bid | 123.92 x 900 |
| Ask | 124.48 x 800 |
| Day's Range | 121.79 - 124.99 |
| 52 Week Range | 85.74 - 169.54 |
| Volume | |
| Avg. Volume | 351,854 |
| Market Cap | 3.748B |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.97 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 142.13 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IRTC
Related Research
- iRhythm Technologies, Inc.Daily – Vickers Top Buyers & Sellers for 11/07/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
- Zacks
iRhythm Technologies (IRTC) Soars 3.9%: Is Further Upside Left in the Stock?
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- GlobeNewswire
Large Real-World Evidence Analysis Demonstrates that Zio® XT Is Associated With the Highest Diagnostic Yield, Lowest Retesting Rates, and Fastest Time to Clinical Diagnosis Compared to Other Ambulatory ECG Monitors
Additional studies presented at ACC.23/WCC reinforce the clinical value of the Zio suite of products and servicesSAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, recently presented the results of multiple new studies at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC).
- GlobeNewswire
Four New Studies Featuring Zio® by iRhythm to be Presented at ACC.23/WCC
iRhythm continues to expand its strong body of clinical and scientific evidence with new research presented by leading clinical investigators at the conference Highlights include a retrospective analysis of comparative effectiveness between ambulatory monitors for arrhythmia diagnosis SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, will hav
